Corporate Banner
Satellite Banner
Chromatography
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Technologies Reports Fourth-Quarter 2012 Results

Published: Tuesday, November 20, 2012
Last Updated: Tuesday, November 20, 2012
Bookmark and Share
Revenues for the fourth fiscal quarter ended October 31, 2012 were $1.77 billion, up 2 percent one year ago.

Fourth-quarter GAAP net income was $425 million, or $1.20 per share. Last year's fourth-quarter GAAP net income was $289 million, or $0.82 per share.

During the fourth quarter, Agilent had intangible amortization of $52 million; acquisition, integration and transformation costs of $40 million; and a donation to the Agilent Technologies Foundation of $10 million. The company also recognized a tax benefit of $227 million. Excluding these items and $3 million of other net charges, Agilent reported fourth-quarter adjusted net income of $303 million, or $0.86 per share.

Agilent CEO Bill Sullivan said, "Agilent's performance in the fiscal fourth quarter met our revenue guidance and exceeded EPS guidance. Despite a very challenging economic environment, the strength of our operating model was evident, with operating margins for the quarter and the year at an all-time high."

Electronic Measurement fourth-quarter revenues declined 5 percent compared to the prior year. Revenues declined across all key markets with the exception of computer and semiconductor markets. Operating margins were 23 percent.

Chemical Analysis revenues were down 3 percent compared to a year ago. Environmental and chemical markets were down, offset by growth in the food and forensics markets. Operating margins were 25 percent.

Life Sciences revenues were flat with last year. Growth in the pharma and environmental markets was offset by a decline in academia and government markets. Operating margins were 18 percent.

Diagnostics and Genomics, which includes the Dako acquisition, had revenues of $156 million, up 125 percent over last year or 1 percent excluding the effects of the Dako acquisition. Operating margins were 17 percent.

Agilent generated $485 million of cash from operations in the quarter. Fourth-quarter ROIC was 19 percent.

Fiscal first-quarter 2013 revenues are expected to be in the range of $1.68 billion to $1.70 billion. Fiscal first-quarter non-GAAP earnings are expected to be in the range of $0.65 to $0.67 per share.

For the full fiscal year 2013, Agilent expects revenue of $7.0 billion to $7.20 billion and non-GAAP earnings of $2.80 to $3.10 per share.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Technologies Opens Folsom Technology Center of Excellence
The new facility expands Agilent’s capabilities for chromatography consumables and hardware, which are used in laboratories around the world and for critical health, safety and product quality decisions.
Thursday, December 01, 2016
Reclaim from the Drain - The Importance of Water Reuse
This infographic explains the importance of reusing water to meet the world's increasing water demand.
Wednesday, October 12, 2016
Agilent, Seoul National University to Collaborate on New Research Center
The facility will support new drug development center in the university's college of pharmacy.
Tuesday, May 13, 2014
Agilent Combines Its Life Sciences and Diagnostics Businesses
Decision follows Agilent's announcement that it plans to separate the company into two independent publicly traded companies.
Thursday, September 19, 2013
Agilent to Acquire Assets from ABC Instrumentación Analítica
The companies have signed a definitive agreement for Agilent to acquire assets from the privately held Mexican distributor.
Thursday, September 05, 2013
Agilent Reports Third-Quarter Results
Revenues were $1.65 billion for the third fiscal quarter ended July 31, 2013, down 4 percent over one year ago.
Thursday, August 15, 2013
Agilent to Host Forensics Webinar
The webinar, which will be held on June 20, will focus on LC/MS/MS methods for cannabinoid and benzodiazepine quantitation in whole blood samples.
Wednesday, June 05, 2013
Scientific News
Cocaine Test Could Lead to Rapid, Low Cost Roadside Testing
Scientists develop urine and oral fluid diagnostic test for cocaine, utilising a compact mass spectrometer.
The Benefits of a Mediterranean-style Diet
A Western-style diet, with more omega-6 fatty acids than the Mediterranean, dysregulates lipid signaling in aged mice and promotes inflammation.
Are Sweeteners as Natural as We Think?
New research study supports stevia’s naturality by identifying nine required molecules present in the dried stevia leaf.
Alarming Glyphosate Levels Found in Foods
Glyphosate has been found at alarming levels in a wide range of best-selling foods across the U.S.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Rapid Identification of Illicit Designer Drugs
New technique can identify commonly used illicit compounds in as little as 15 seconds.
Enhancing On-line Biological Sample Processing
New techniques are required to meet emerging demands on biopharmaceutical analysis.
Early Warning System for Colorectal Cancer
Potential new diagnostic tool identified for the second most common cancer in the world.
Steroid Screening with LC-MS
Researchers developed and validated a label-free assay for detection of steroid activity using LC-MS techniques.
A Simple Tool for Toxicological Analysis
In this study, GC-MS is used for the determination of clozapine, and five antidepressants in human plasma, serum and whole blood.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!